14 Leukemia Clinical Trials in Sarasota, FL (2026)

Q: How do I join a clinical trial in Sarasota?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Sarasota research site will contact you.

Recruiting Leukemia Studies in Sarasota

NCT06040541Recruiting

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors....

Sarasota, FLPHASE1604 participantsRevolution Medicines, Inc.

View Study Details

NCT05131022Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies....

Sarasota, FLPHASE1572 participantsNurix Therapeutics, Inc.

View Study Details

NCT06128551Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors....

Sarasota, FLPHASE1534 participantsRevolution Medicines, Inc.

View Study Details

NCT07218146Recruiting

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer....

Sarasota, FLPHASE3480 participantsZai Lab (Shanghai) Co., Ltd.

View Study Details

NCT05581004Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizum...

Sarasota, FLPHASE1450 participantsGenentech, Inc.

View Study Details

NCT04065399Recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled...

Sarasota, FLPHASE1447 participantsSyndax Pharmaceuticals

View Study Details

NCT07066657Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic...

Sarasota, FLPHASE1405 participantsArriVent BioPharma, Inc.

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

Sarasota, FLPHASE1290 participantsCrescent Biopharma, Inc.

View Study Details

NCT06876662Recruiting

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-...

Sarasota, FLPHASE4279 participantsEli Lilly and Company

View Study Details

NCT04830137Recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies....

Sarasota, FLPHASE1248 participantsNurix Therapeutics, Inc.

View Study Details

NCT07046923Recruiting

A Study of LY4175408 in Participants With Advanced Cancer

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the blood...

Sarasota, FLPHASE1240 participantsEli Lilly and Company

View Study Details

NCT07458347Recruiting

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally to adults with advanced or metastatic solid tumors with certain KRAS mutatio...

Sarasota, FLPHASE1145 participantsKestrel Therapeutics, Inc.

View Study Details

NCT07221500Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent...

Sarasota, FLPHASE2100 participantsNurix Therapeutics, Inc.

View Study Details

NCT06150664Recruiting

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Do...

Sarasota, FLPHASE185 participantsCompass Therapeutics

View Study Details

About Leukemia Clinical Trials in Sarasota

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 14 leukemia clinical trials recruiting participants in Sarasota, FL. These studies are seeking a combined 4,879 participants. Research is being sponsored by Revolution Medicines, Inc., Nurix Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Sarasota — FAQ

Are there leukemia clinical trials in Sarasota?

Yes, there are 14 leukemia clinical trials currently recruiting in Sarasota, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Sarasota?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Sarasota research site will contact you about next steps.

Are clinical trials in Sarasota free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Sarasota studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 14 active trials in Sarasota are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated July 17, 2026 from ClinicalTrials.gov